Blog
Tackle immense Medical Information inquiry volumes with AI innovation
Transforming MI Workflows with AI: Efficiency, Innovation, and Customer Satisfaction
Nov 19, 2024

As drug companies expand therapeutic access to new regions and patient populations, the task of safely disseminating Medical Information (MI) has grown more complex than ever. MI teams handle the collection and distribution of data on therapeutics to ensure their safe usage and have traditionally taken inquiries via a human-only call center model. However, as inquiries grow in volume, complexity, and diversity, and patient and healthcare provider needs evolve, many drug companies are considering how implementing technology like AI, ChatGPT, and GenAI into MI workflows can increase efficiency, improve the customer experience, and minimize burnout for MI professionals.

What challenges are MI teams facing?

Expanded access to critical therapies is integral to reducing the global disease burden. That said, delivering therapeutics to a wider range of regions with distinct regulatory protocols has increased the volume and diversity of MI inquiries. Furthermore, the continued growth of cell and gene therapies means that MI experts must be equipped to solve and address more complex inquiries as they relate to more elaborate biological processes. As these factors compound, drug companies are asking the following questions:

  • How do we redistribute inquiry volume to ensure that MI staff has the bandwidth to work on complex projects?
  • How can we continue to provide high-quality customer service that leaves the inquirer feeling satisfied?
  • Where can we innovate to improve efficiency and quality for both MI experts as well as the patients and healthcare providers they interact with?

As the therapeutic landscape evolves, the need to address these questions is intensifying, leading many to turn to AI technology to reduce the MI burden.

Where can I implement AI into existing workflows?

If your team is considering whether AI can make your processes more efficient, the answer is simple: it can. Though companies are still navigating skepticism around AI, the goal of implementing AI into MI services is to create synergy between human MI experts and AI to deliver safe, ethical information and ease burnout. Nevertheless, drug companies are already setting a precedent by leveraging AI to:

  • Support high inquiry volumes while minimizing resource impact.
  • Create engagement options to reduce inquiry abandonment and enhance customer satisfaction.
  • Provide customers with a choice between an AI agent and a human specialist.
  • Leverage real-time data analysis to help human agents better serve customers.

Ready to learn more?

In a recent Medical Information webinar, IQVIA experts, Simon Johns, Director, Medical Information and Marketed Product Safety, and Louise Molloy, Associate Director, Medical Information and Pharmacovigilance, discussed how the MI landscape has grown more complex and difficult to manage with just the traditional human-only model, and how, to alleviate these challenges, many drug sponsors are using AI to improve MI workflows. If you are looking to build AI into your technology roadmap, download the white paper, “Harnessing AI Beyond Chatbots to Innovate Medical Information Offerings.”

Related solutions

Contact Us